ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OGN vs ACAD // EV/EBITDA & P/E VALUATION

Organon & Co. (NYSE) VS. ACADIA Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: OGN 5 — ACAD 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OGN VS. ACAD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OGN ACAD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 53.30% 91.70% -38.40 ACAD /gross-margins <GO>
Return on Invested Capital (ROIC) 24.90% 7.90% +17.00 OGN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 31.2x — TIE /valuation <GO>
Free Cash Flow Yield 14.83% 2.94% +11.89 OGN /fcf-yield <GO>
Operating Margin — 9.80% — TIE /operating-margins <GO>
Net Profit Margin 3.00% 36.50% -33.50 ACAD /net-margins <GO>
Revenue Growth (YoY) -2.90% 11.90% -14.80 ACAD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 2.43% 0.00% +2.43 OGN /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.26 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 ACAD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 67.8 45.5 +22.24 OGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 18.0x 8.5x +9.50 ACAD /forward-pe <GO>
Enterprise Scale & Market Cap $3.63B $3.58B $49.6M OGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OGN REV ACAD REV OGN GROSS % ACAD GROSS % OGN FCF ACAD FCF
FY 2025 $6.22B $1.07B 53.3% 91.7% $538.0M $105.1M
FY 2024 $6.40B $957.8M 58.0% 91.5% $764.0M $157.2M
FY 2023 $6.26B $726.4M — — $799.0M $16.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OGN // BETA —
ACAD // BETA —